Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view-Reference-Cited by-同舟云学术

Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view

Published:2020-05-04 Issue:2 Volume:105 Page:203-215
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Thielen Frederick W.¹^ORCID,Dongen‐Leunis Annemieke¹,Arons Alexander M. M.²,Ladestein Judith R.²,Hoogerbrugge Peter M.³,Uyl‐de Groot Carin A.¹^ORCID

Affiliation:

1. Erasmus School of Health Policy & Management/Institute for Medical Technology Assessment Erasmus University Rotterdam The Netherlands

2. Novartis Pharma B.V Amsterdam The Netherlands

3. Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13427

Reference48 articles.

1. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

2. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

3. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

4. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.

5. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Availability and financing of CAR-T cell therapies: A cross-country comparative analysis;Health Policy;2024-11

2. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review;Value in Health;2024-08

3. Lipid-based nanosystems: the next generation of cancer immune therapy;Journal of Hematology & Oncology;2024-07-19

4. A Review of the Cost-Effectiveness Evidence for FDA-Approved Cell and Gene Therapies;Human Gene Therapy;2024-06-01

5. Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study;Applied Health Economics and Health Policy;2024-04-29